The purpose of this clinical trial is to test the safety and effectiveness of additional COVID-19 booster doses in people who have already received a primary COVID-19 vaccination series and booster dose. Participants will have completed a primary COVID-19 vaccination series (2 doses of Pfizer, 2 doses of Moderna, or 1 dose of Johnson & Johnson) and received a booster at least 16 weeks prior to joining the study.
Category: Past Studies
“Mix ‘n Match” Booster COVID-19 Vaccine Trial
This is a Phase 1/2 COVID-19 vaccine booster trial. The purpose of this clinical trial is to test the safety and effectiveness of a booster dose of the Novavax sub-unit protein vaccine in people who have received an EUA vaccine series.
Gritstone COVID-19 Vaccine Trial
The purpose of this trial is to test investigational chimpanzee Adenovirus and self-amplifying mRNA prime-boost prophylactic vaccines against SARS-CoV-2 in healthy adults.
Immunity Study
We have identified a genetic marker in people of African descent that could increase the risk of acquiring HIV. The purpose of this study is to find out whether factors in the genital area of the body can change how your body fights HIV.
VIVA Trial
The VIVA Clinical Trial (Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia) will test whether the Human Papillomavirus (HPV) vaccine can improve the health of people who have been previously diagnosed with pre-cancerous lesions.
More: Past Studies
VRC studies over the decades
HSV and HIV Tissue Reservoirs Study
The purpose of this study is to understand whether immune responses to herpes simplex virus type 2 bring HIV infected cells to the genital tract in people with HIV infection. The study will last for 5 months and involve 8 clinic visits.
Novavax COVID-19 Vaccine Trial
This is a clinical trial of a Phase 3 vaccine for the prevention of COVID-19. Our research site is testing the SARS-CoV-2 recombinant spike protein nanoparticle vaccine that is now being developed as part of Operation Warp Speed by a new NIH network – the Coronavirus Prevention Network, or CoVPN – and Novavax as the pharmaceutical partner.